<DOC>
	<DOCNO>NCT00600301</DOCNO>
	<brief_summary>Diabetic macular edema common cause visual loss among patient diabetic retinopathy . Pars plana vitrectomy report effective treatment diabetic macular edema . Previous report show limited improvement visual acuity macular thickness posterior intraoperative triamcinolone acetonide . Bevacizumab intravitreal injection proven effective treatment diabetic macular edema , recent publication . The purpose study evaluate whether vitrectomy without intravitreal triamcinolone acetonide bevacizumab injection affect vision outcome macular thickness patient diabetic macular edema .</brief_summary>
	<brief_title>Vitrectomy Without Internal Limiting Membrane Removal Treatment Diffuse Diabetic Macular Edema : Comparative Kenalog Vs Bevacizumab Intravitreal Injection Vs Control Study</brief_title>
	<detailed_description />
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Triamcinolone hexacetonide</mesh_term>
	<mesh_term>Triamcinolone Acetonide</mesh_term>
	<mesh_term>Triamcinolone</mesh_term>
	<mesh_term>Triamcinolone diacetate</mesh_term>
	<criteria>Diffuse diabetic macular edema Non proliferative diabetic retinopathy No VPP previa No previous treament laser , Triamcinolone acetonide , Bevacizumab Proliferative diabetic retinopathy Previous par plana vitrectomy Previous treatment diabetic macular edema Focal macular edema Macular Ischemia</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>January 2008</verification_date>
	<keyword>Macula</keyword>
	<keyword>Edema</keyword>
</DOC>